BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AstraZeneca readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AstraZeneca's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06267729-11145@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:AZD0754: Phase 1/2 readout est. (NCT06267729)
DESCRIPTION:AZD0754\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD0754
  in Participants With Metastatic Prostate Cancer\nEstimated primary comple
 tion: 24 November 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/azd0754#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06267729
URL:https://assetmemo.bio/drug/azd0754#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081633-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab With Lenvatinib as First-line Treatment in Patients 
 With Unresectable Hepatocellular Carcinoma\nEstimated primary completion: 
 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07081633
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0722291
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: A Phase IIb Study to Evaluate the Effect of Dapagliflozin i
 n Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in P
 articipants With Chronic Kidney Disease and High Blood Pressure.\nEstimate
 d primary completion: 10 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07222917
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607627-11169@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Klygefa (Gefurulimab): Phase 3 readout est. (NCT06607627)
DESCRIPTION:Klygefa (Gefurulimab)\, phase 3\, Generalized Myasthenia Gravis
 .\nStudy: PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatri
 c Patients With AChR+ Generalized Myasthenia Gravis\nEstimated primary com
 pletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gefurulimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06607627
URL:https://assetmemo.bio/drug/gefurulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06402331-11154@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Zadavotide guraxetan: Phase 2 readout est. (NCT06402331)
DESCRIPTION:Zadavotide guraxetan\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSM
 A-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstima
 ted primary completion: 23 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06402331
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959615-2145@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06959615)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: A Phase I/IIa Study of JAB-23E73
  in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06959615
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303532-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05303532)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Roll Over StudY for Patients Who 
 Have Completed a Previous Oncology Study With Durvalumab\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05303532
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000136-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000136)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With HeFH\nEstimated primary completion: 4 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07000136
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925803-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05925803)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Sclerosis.\nStudy: Determine E
 ffectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)\nEstimated prima
 ry completion: 6 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05925803
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000123-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000123)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With Clinical ASCVD or at Risk for a First ASCVD Event\nEstimated p
 rimary completion: 11 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07000123
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706817-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06706817)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyposis Initiating Treatment With Tezepelumab\nEstimated primar
 y completion: 13 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06706817
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05374603)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Savo
 litinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Meta
 static NSCLC\nEstimated primary completion: 18 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151964-149@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Lenbelintide: Phase 1/2 readout est. (NCT06151964)
DESCRIPTION:Lenbelintide\, phase 1/2\, Obesity.\nStudy: A Trial to Learn Ho
 w Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or 
 Without Type 2 Diabetes Who Are Living With Obesity and Overweight\nEstima
 ted primary completion: 29 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lenbelintide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06151964
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464587-1558@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:TQC3721: Phase 3 readout est. (NCT07464587)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate
 -to-Severe Chronic Obstructive Pulmonary Disease\nEstimated primary comple
 tion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tqc3721#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07464587
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06530849-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06530849)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy of GC012F Injection in Subjects With Refractory Systemic Lupus Erythe
 matosus\nEstimated primary completion: 1 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06530849
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06271837)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of T-DXd as Monotherapy or in Combination With Ant
 i-cancer Agents in Patients With Selected HER2-expressing Tumors\nEstimate
 d primary completion: 10 February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06271837
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215702-895@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:AZD4144: Phase 2 readout est. (NCT07215702)
DESCRIPTION:AZD4144\, phase 2.\nStudy: A Study to Investigate the Efficacy\
 , Safety\, and Tolerability of AZD4144in Participants With Sepsis-associat
 ed Acute Kidney Injury.\nEstimated primary completion: 11 February 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/azd4144#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07215702
URL:https://assetmemo.bio/drug/azd4144#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02972840-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT02972840)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: A Study of BR Alone Versus in 
 Combination With Acalabrutinib in Subjects With Previously Untreated MCL\n
 Estimated primary completion: 15 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT02972840
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087835-536@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Zibotentan + Dapagliflozin: Phase 3 readout est. (NCT06087835)
DESCRIPTION:Zibotentan + Dapagliflozin\, phase 3\, Chronic Kidney Disease.\
 nStudy: Study to Investigate Efficacy\, Safety\, and Tolerability of Zibot
 entan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic
  Kidney Disease and High Proteinuria (ZENITH High Proteinuria)\nEstimated 
 primary completion: 18 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06087835
URL:https://assetmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834932-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Laroprovstat: Phase 2/3 readout est. (NCT06834932)
DESCRIPTION:Laroprovstat\, phase 2/3\, Atherosclerotic Cardiovascular Disea
 se.\nStudy: A Study to Evaluate the Efficacy\, Safety\, and Pharmacokineti
 cs of AZD0780 in Participants With Dyslipidaemia\nEstimated primary comple
 tion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/laroprovstat#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06834932
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629234-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05629234)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3.\nStudy: Roll Over StudY for P
 atients Who Have Completed a Previous Oncology Study With Osimertinib (TAG
 RISSO) (ROSY-T)\nEstimated primary completion: 22 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05629234
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04529772-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT04529772)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : A Combination of Acalabrutinib With R-CHOP in Subjects With Previously U
 ntreated Non-GCB DLBCL (ACE-LY-312)\nEstimated primary completion: 22 Febr
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04529772
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138133-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05138133)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: P
 hase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lu
 pus Nephritis\nEstimated primary completion: 23 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05138133
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-1558@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TQC3721: Phase 3 readout est. (NCT07147946)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Pati
 ents With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tqc3721#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07147946
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749457-11173@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:AZD7760: Phase 1/2 readout est. (NCT06749457)
DESCRIPTION:AZD7760\, phase 1/2.\nStudy: A Study to Evaluate AZD7760 Safety
  and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stag
 e Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa
 )\nEstimated primary completion: 8 March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/azd7760#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06749457
URL:https://assetmemo.bio/drug/azd7760#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04482309-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04482309)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Phase 2 Study of T-
 DXd in Patients With Selected HER2 Expressing Tumors\nEstimated primary co
 mpletion: 23 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04482309
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421963-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Olaparib: Phase 3 readout est. (NCT04421963)
DESCRIPTION:Olaparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Roll Over StudY for Patients Who Have Completed a Previous Oncology Stud
 y With Olaparib\nEstimated primary completion: 6 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04421963
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630765
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With Heart Failure and Impaired Kidney Function\nEstimated primary comp
 letion: 16 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06307652
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285213-11172@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:AZD5148: Phase 2 readout est. (NCT07285213)
DESCRIPTION:AZD5148\, phase 2.\nStudy: Prevention of Recurrent C. Difficile
  Infection Study With AZD5148 Monoclonal Antibody\nEstimated primary compl
 etion: 20 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /azd5148#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07285213
URL:https://assetmemo.bio/drug/azd5148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05774951-2423@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05774951)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years
  of Standard Adjuvant Endocrine Therapy\nEstimated primary completion: 20 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camizestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05774951
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)
 \, With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Pre
 viously Untreated CLL\nEstimated primary completion: 30 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olaparib: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Me
 tastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06909825
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trast
 uzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-B
 reast09)\nEstimated primary completion: 3 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Durvalumab\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study of 
 the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing 
 Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04379596
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Olaparib: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Study of Pembrolizumab With Concurr
 ent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapa
 rib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-0
 12)\nEstimated primary completion: 5 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04380636
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-885@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Paroxysmal Nocturnal Hemogl
 obinuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or
  Eculizumab in Pediatric Participants With PNH Who Have Clinically Signifi
 cant Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-5401@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholeste
 rolaemia\nEstimated primary completion: 28 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07619118
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932263-1426@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:tozorakimab: Phase 2 readout est. (NCT06932263)
DESCRIPTION:tozorakimab\, phase 2\, Asthma.\nStudy: Dose Range Finding Stud
 y to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled
  Asthma on Medium-to-High Dose Inhaled Corticosteroids\nEstimated primary 
 completion: 7 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tozorakimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06932263
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06473779)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Open-label S
 tudy to Assess Reduction of Background Asthma Medication While Sustaining 
 Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yr
 s With Severe Asthma.\nEstimated primary completion: 25 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473779
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2423@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Etcamah (Camizestrant): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Etcamah (Camizestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to 
 Evaluate the Safety\, and Tolerability of AZD8421 Alone or in Combination 
 in Participants With Selected Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/camizestrant#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795022-11176@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:AZD9793: Phase 1/2 readout est. (NCT06795022)
DESCRIPTION:AZD9793\, phase 1/2.\nStudy: First in Human Study to Evaluate A
 ZD9793 in Participants With Advanced or Metastatic Solid Tumours\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/azd9793#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06795022
URL:https://assetmemo.bio/drug/azd9793#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792695-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06792695)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: A Study of Novel Study Intervent
 ions and Combinations in Participants With Colorectal Cancer\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06792695
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04550260-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04550260)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Study of Durvalumab Versus Placeb
 o in Combination With Definitive Chemoradiation Therapy in Patient With ES
 CC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04550260
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157787-11163@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:ALXN1920: Phase 2 readout est. (NCT07157787)
DESCRIPTION:ALXN1920\, phase 2\, Primary Membranous Nephropathy.\nStudy: St
 udy of ALXN1920 in Adult Participants With Primary Membranous Nephropathy 
 (PMN)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/alxn1920#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07157787
URL:https://assetmemo.bio/drug/alxn1920#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610837-11159@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:AZD2389: Phase 2 readout est. (NCT07610837)
DESCRIPTION:AZD2389\, phase 2.\nStudy: Study of AZD2389 Safety\, Tolerabili
 ty\, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advan
 ced Fibrosis\nEstimated primary completion: 7 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azd2389#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07610837
URL:https://assetmemo.bio/drug/azd2389#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzu
 mab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocy
 tic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007793-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07007793)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3.\nStudy: Parent Study: A Study 
 to Assess Efficacy and Safety of Baxdrostat in Participants With Primary A
 ldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA
  Main Study.\nEstimated primary completion: 27 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07007793
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Durvalumab\, phase 3\, Breast Cancer.\nStudy: A Phase III Study
  of Dato-DXd With or Without Durvalumab Compared With Investigator's Choic
 e of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1
  Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breas
 t Cancer (TROPION-Breast05)\nEstimated primary completion: 28 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06103864
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06448754)
DESCRIPTION:Volrustomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Vol
 rustomig Priming Regimens Exploratory Phase II Platform Study\nEstimated p
 rimary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120349-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05120349)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Global Study to Assess the Effects of Osimertinib in Participant
 s With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection\nEsti
 mated primary completion: 2 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05120349
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596784-885@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07596784)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Myasthenia Gravis.\nStudy: 
 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Gen
 eralized Myasthenia Gravis (gMG)\nEstimated primary completion: 24 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759678
 4
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082738-11161@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:AZD6793: Phase 2 readout est. (NCT07082738)
DESCRIPTION:AZD6793\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: A Study to Investigate the Effect of AZD6793 in Participants With Mode
 rate to Very Severe Chronic Obstructive Pulmonary Disease\nEstimated prima
 ry completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azd6793#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07082738
URL:https://assetmemo.bio/drug/azd6793#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Durvalumab\, phase 3\, Breast Cancer.\nStudy: A Study of Dato-D
 Xd With or Without Durvalumab Versus Investigator's Choice of Therapy in P
 atients With Stage I-III Triple-negative Breast Cancer Without Pathologica
 l Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)\nEsti
 mated primary completion: 1 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05629585
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participants 
 With Advanced/Metastatic Solid Malignancies\nEstimated primary completion:
  29 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120491-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Saruparib: Phase 3 readout est. (NCT06120491)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib (AZD53
 05) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer
  Receiving Physician's Choice New Hormonal Agents\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06120491
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850234-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT05850234)
DESCRIPTION:AZD0120\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0120 in Rela
 psed/Refractory Multiple Myeloma (DURGA-1)\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd01
 20#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5850234
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05801029)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate Safety and Efficacy of Osimertinib and Amiv
 antamab in Participants With Non-small Cell Lung Cancer With Common Epider
 mal Growth Factor Receptor Mutations\nEstimated primary completion: 1 Octo
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 01029
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Urothelial Carcinoma.\nStudy
 : Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Age
 nts in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT05950945)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormon
 e Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 M
 etastatic Breast Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05950
 945
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824987-11160@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Opemalirsen: Phase 2 readout est. (NCT06824987)
DESCRIPTION:Opemalirsen\, phase 2.\nStudy: Dose-Ranging Safety\, Tolerabili
 ty\, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kid
 ney Disease\nEstimated primary completion: 4 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/opemalirsen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06824987
URL:https://assetmemo.bio/drug/opemalirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471257-3562@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0647125
 7)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: A
  Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in 
 Symptomatic Chinese Adults With Asthma\nEstimated primary completion: 4 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/albuterol
 -budesonide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06471257
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160608-10336@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:ALXN1820: Phase 2 readout est. (NCT07160608)
DESCRIPTION:ALXN1820\, phase 2\, ANCA-Associated Vasculitis.\nStudy: Safety
  and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil C
 ytoplasmic Antibody (ANCA)-Associated Vasculitis\nEstimated primary comple
 tion: 11 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alxn1820#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07160608
URL:https://assetmemo.bio/drug/alxn1820#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744647-11164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Cevolisiran: Phase 2 readout est. (NCT06744647)
DESCRIPTION:Cevolisiran\, phase 2\, Antibody-Mediated Rejection.\nStudy: Ph
 ase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After
  Kidney Transplantation\nEstimated primary completion: 11 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cevolisiran#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06744647
URL:https://assetmemo.bio/drug/cevolisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307665-3562@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:Airsupra (albuterol / budesonide): Phase 3 readout est. (NCT0630766
 5)
DESCRIPTION:Airsupra (albuterol / budesonide)\, phase 3\, Asthma.\nStudy: E
 valuating the Efficacy and Safety of PT027 Compared With PT007 Administere
 d As Needed in Participants 12 to < 18 Years of Age With Asthma\nEstimated
  primary completion: 13 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/albuterol-budesonide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06307665
URL:https://assetmemo.bio/drug/albuterol-budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044336-2375@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Puxitatug samrotecan: Phase 3 readout est. (NCT07044336)
DESCRIPTION:Puxitatug samrotecan\, phase 3\, Endometrial Cancer.\nStudy: Pu
 xitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected
  Endometrial Cancer (Bluestar-Endometrial01)\nEstimated primary completion
 : 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pu
 xitatug-samrotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07044336
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination Therapies in
  Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
 \nEstimated primary completion: 22 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Olaparib: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Placebo-controlled\, Study of Concu
 rrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab 
 and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell 
 Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary complet
 ion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olaparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04624204
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970172-873@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT05970172)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chr
 onic Kidney Disease\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/roxadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05970172
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e III\, Open-label\, First-line Study of Dato-DXd in Combination With Durv
 alumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alter
 ations\nEstimated primary completion: 1 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-7646@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Capivasertib: Phase 3 readout est. (NCT04862663)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER
 2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capivasertib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04862
 663
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624450-1426@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:tozorakimab: Phase 3 readout est. (NCT05624450)
DESCRIPTION:tozorakimab\, phase 3.\nStudy: Efficacy and Safety of Tozorakim
 ab in Patients Hospitalised for Viral Lung Infection Requiring Supplementa
 l Oxygen\nEstimated primary completion: 4 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tozorakimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05624450
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Rilvegostomig\, phase 2.\nStudy: A Study of Novel Agents or Com
 binations as Perioperative Treatment in Participants With Locally Advanced
  Resectable Gastroesophageal Adenocarcinoma\nEstimated primary completion:
  9 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ril
 vegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07069712
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276581-6198@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:AZD1163: Phase 2 readout est. (NCT07276581)
DESCRIPTION:AZD1163\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to In
 vestigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid A
 rthritis\nEstimated primary completion: 12 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azd1163#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07276581
URL:https://assetmemo.bio/drug/azd1163#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079671-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06079671)
DESCRIPTION:Volrustomig\, phase 3\, Cervical Cancer.\nStudy: Study of Volru
 stomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Ce
 rvical)\nEstimated primary completion: 26 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06079671
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Volrustomig\, phase 2\, Gastric Cancer.\nStudy: Novel Combinati
 ons in Participants With Locally Advanced Unresectable or Metastatic Gastr
 ic or Gastroesophageal Junction Adenocarcinoma\nEstimated primary completi
 on: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /volrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05702229
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-7646@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capivasertib: Phase 3 readout est. (NCT06764186)
DESCRIPTION:Capivasertib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combinatio
 n With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relaps
 ed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Pr
 actice in Spain\nEstimated primary completion: 30 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capivasertib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/capivasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830798-885@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06830798)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3.\nStudy: Double-blind\, Rando
 mized\, Placebo-controlled\, Multicenter Study to Evaluate the Efficacy an
 d Safety of Ravulizumab Administered Intravenously in Adult Participants a
 t High Risk of Delayed Graft Function After Kidney Transplantation\nEstima
 ted primary completion: 30 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06830798
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283966-7606@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumarate):
  Phase 3 readout est. (NCT06283966)
DESCRIPTION:Breztri Aerosphere (Budesonide/glycopyrrolate/formoterol fumara
 te)\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStudy: A Study Eva
 luating the Efficacy of Budesonide\, Glycopyrronium and Formoterol Fumarat
 e Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive
  Pulmonary Disease\nEstimated primary completion: 3 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/budesonide-glycopyrrolate-fo
 rmoterol-fumarate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06283966
URL:https://assetmemo.bio/drug/budesonide-glycopyrrolate-formoterol-fumarat
 e#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06183931-11166@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Cliramitug: Phase 3 readout est. (NCT06183931)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM\nEs
 timated primary completion: 6 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06183931
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07088926-11171@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271209
DTEND;VALUE=DATE:20271210
SUMMARY:AZD0292: Phase 2 readout est. (NCT07088926)
DESCRIPTION:AZD0292\, phase 2.\nStudy: A Study to Evaluate the Efficacy\, S
 afety\, and PK of AZD0292 Administered IV in Participants 12 Years of Age 
 and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonizat
 ion\nEstimated primary completion: 9 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azd0292#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07088926
URL:https://assetmemo.bio/drug/azd0292#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07427394-2423@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07427394)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study to Evaluate the Safety and Tolerability of Camizestr
 ant in Combination With Atirmociclib in Women With Advanced Breast Cancer\
 nEstimated primary completion: 28 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/camizestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07427394
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029737-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07029737)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  to Evaluate Acalabrutinib\, in Combination With the R-CHOP Standard of Ca
 re\, for Previously Untreated Mantle Cell Lymphoma in Spain\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07029737
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137118-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280106
DTEND;VALUE=DATE:20280107
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT06137118)
DESCRIPTION:Surovatamig\, phase 1/2.\nStudy: AZD0486 as Monotherapy in B-ce
 ll Acute Lymphoblastic Leukaemia\nEstimated primary completion: 6 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0613711
 8
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06455449-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT06455449)
DESCRIPTION:Anifrolumab\, phase 3\, Idiopathic Inflammatory Myopathies.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Anifrolumab Adminis
 tered as Subcutaneous Injection and Added to Standard of Care Compared Wit
 h Placebo Added to Standard of Care in Adult Participants With Idiopathic 
 Inflammatory Myopathies (Polymyositis and Dermatomyositis)\nEstimated prim
 ary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06455449
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774403-11171@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280118
DTEND;VALUE=DATE:20280119
SUMMARY:AZD0292: Phase 2 readout est. (NCT07774403)
DESCRIPTION:AZD0292\, phase 2.\nStudy: A Study of AZD0292 in Chinese Partic
 ipants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
 \nEstimated primary completion: 18 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd0292#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07774403
URL:https://assetmemo.bio/drug/azd0292#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3333@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Vemzatatug vedotin: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Vemzatatug vedotin\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0
 305 as Monotherapy or in Combination With Anticancer Agents in Participant
 s With Multiple Myeloma\nEstimated primary completion: 24 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vemzatatug-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/vemzatatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205822-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07205822)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Dato-DXd in Inoperable or Metastatic Hormone Re
 ceptor-positive\, HER2 IHC 0 Breast Cancer\nEstimated primary completion: 
 2 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dato
 potamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07205822
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: Study of AZD9574 as
  Monotherapy and in Combination With Anti-cancer Agents in Participants Wi
 th Advanced Solid Malignancies\nEstimated primary completion: 7 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05417594
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363642-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07363642)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Phase 3b Stu
 dy in Patients With Severe Asthma Treated With Tezepelumab\nEstimated prim
 ary completion: 7 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363642
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686120-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07686120)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participant
 s With Uncontrolled Hypertension.\nEstimated primary completion: 9 Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076861
 20
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174987-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06174987)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study to Provide Co
 ntinued Access to and Assess Long-Term Safety of the Study Drug(s)\nEstima
 ted primary completion: 17 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06174987
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06512883-1322@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT06512883)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3.\nStudy: A Trial to Investigat
 e Benralizumab in Children With Eosinophilic Diseases\nEstimated primary c
 ompletion: 20 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benralizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06512883
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295847-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT07295847)
DESCRIPTION:AZD0120\, phase 1/2\, Rheumatoid Arthritis.\nStudy: A Study of 
 AZD0120 in Autoimmune Diseases\nEstimated primary completion: 22 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07295847
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0626887
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Investigate the Efficacy and Safety of
  Baxdrostat in Combination With Dapagliflozin on CKD Progression in Partic
 ipants With CKD and High Blood Pressure.\nEstimated primary completion: 24
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268873
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520162-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07520162)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Tr
 eatment With Tezepelumab\nEstimated primary completion: 1 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07520162
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943833-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06943833)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: A Study of Vol
 rustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
 \nEstimated primary completion: 13 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06943833
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350097-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06350097)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label Study of First-line Osimertinib With or Wit
 hout Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-s
 mall Cell Lung Cancer\nEstimated primary completion: 21 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350097
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775404-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07775404)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Study to Investigat
 e the Efficacy and Safety of Elecoglipron in Asian Participants With Obesi
 ty or Overweight With or Without Type 2 Diabetes Mellitus\nEstimated prima
 ry completion: 6 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elecoglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07775404
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526793-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280421
DTEND;VALUE=DATE:20280422
SUMMARY:Surovatamig: Phase 2 readout est. (NCT06526793)
DESCRIPTION:Surovatamig\, phase 2\, Follicular Lymphoma.\nStudy: Surovatami
 g (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) 
 B-cell NHL\nEstimated primary completion: 21 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06526793
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662213-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662213)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Fi
 nd Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Me
 llitus by Comparing it With Semaglutide\, a Medicine Already Used to Treat
  Type 2 Diabetes Mellitus\nEstimated primary completion: 23 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07662213
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664553-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07664553)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin\nEst
 imated primary completion: 23 May 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07664553
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009836-2032@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Orpathys (Savolitinib): Phase 3 readout est. (NCT05009836)
DESCRIPTION:Orpathys (Savolitinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+
 /MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 
 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savoliti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05009836
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023589-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06023589)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: A Study to I
 nvestigate the Efficacy and Safety of Tezepelumab Compared With Placebo in
  Children 5 to < 12 Years Old With Severe Asthma\nEstimated primary comple
 tion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06023589
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2163@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertin
 ib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07079475
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04995523-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT04995523)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participan
 ts With Advanced or Metastatic NSCLC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0499
 5523
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731478-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06731478)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of TDXd\, Chemo
 therapy\, Pembrolizumab\, and Trastuzumab in First-Line Metastatic HER2-Po
 sitive Gastric or Gastroesophageal Junction Cancer\nEstimated primary comp
 letion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06731478
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467357-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06467357)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Phase 3
  Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing B
 iliary Tract Cancer\nEstimated primary completion: 12 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06467357
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391657-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280614
DTEND;VALUE=DATE:20280615
SUMMARY:AZD0120: Phase 3 readout est. (NCT07391657)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparing
  AZD0120\, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) 
 and CD19\, Versus Standard Regimens in Participants With Relapsed Refracto
 ry Multiple Myeloma (DURGA-4)\nEstimated primary completion: 14 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07391657
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123454-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT07123454)
DESCRIPTION:Surovatamig\, phase 1/2\, B-Cell Non-Hodgkin Lymphoma.\nStudy: 
 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticance
 r Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymph
 oma\nEstimated primary completion: 4 July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07123454
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662109-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662109)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of the Combination of Elecogli
 pron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus\nEstimated 
 primary completion: 5 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07662109
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662135-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280713
DTEND;VALUE=DATE:20280714
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662135)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Functio
 n on Background Dapagliflozin\nEstimated primary completion: 13 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07662135
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662044)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Alone or in Co
 mbination With Dapagliflozin Compared With Placebo in Adults With Type 2 D
 iabetes Mellitus\nEstimated primary completion: 14 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07662044
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667803-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07667803)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Master Protocol to 
 Investigate Efficacy and Safety of Elecoglipron in Participants With Obesi
 ty or Overweight With or Without T2DM\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 67803
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Saruparib\, phase 1/2\, Ovarian Cancer.\nStudy: Phase I/IIa Stu
 dy of AZD5335 as Monotherapy and Combination Therapy in Participants With 
 Solid Tumors\nEstimated primary completion: 4 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/saruparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776509-149@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07776509)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Partic
 ipants With Obesity or Overweight With Weight-related Comorbidity With or 
 Without Type 2 Diabetes Mellitus\nEstimated primary completion: 9 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0777650
 9
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784270-149@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784270)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and O
 besity or Overweight\nEstimated primary completion: 9 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784270
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784725-149@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07784725)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate E
 ffect of AZD6234 in Adult Participants With Obesity or Overweight With Wei
 ght-related Comorbidity Without Type 2 Diabetes Mellitus\nEstimated primar
 y completion: 11 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenbelintide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07784725
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751848-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07751848)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have A
 ctive Mod-severe Systemic Lupus Erythematosus\nEstimated primary completio
 n: 25 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 ifrolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07751848
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06960577-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06960577)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Perioperative Du
 rvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder 
 Cancer (NIAGARA-2)\nEstimated primary completion: 30 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06960577
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07922330-149@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Lenbelintide: Phase 3 readout est. (NCT07922330)
DESCRIPTION:Lenbelintide\, phase 3\, Obesity.\nStudy: A Study to Evaluate t
 he Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adu
 lts Who Are Obese or Overweight. These Participants May or May Not Also Ha
 ve Type 2 Diabetes\nEstimated primary completion: 15 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenbelintide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07922330
URL:https://assetmemo.bio/drug/lenbelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557420-885@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07557420)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3.\nStudy: Efficacy\, Safety\, 
 Pharmacokinetics\, Pharmacodynamics\, and Immunogenicity Study of Ravulizu
 mab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)\
 nEstimated primary completion: 19 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07557420
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816666-11153@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07816666)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of P
 latinum-sensitive Relapsed Epithelial Ovarian Cancer\nEstimated primary co
 mpletion: 29 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/torvutatug-samrotecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07816666
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05835310-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281005
DTEND;VALUE=DATE:20281006
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05835310)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
 n Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic L
 upus Erythematosus in Pediatric Participants\nEstimated primary completion
 : 5 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ani
 frolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05835310
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109219-11147@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281011
DTEND;VALUE=DATE:20281012
SUMMARY:AZD4512: Phase 1/2 readout est. (NCT07109219)
DESCRIPTION:AZD4512\, phase 1/2.\nStudy: Study of AZD4512 Monotherapy or in
  Combination With Anticancer Agents in Participants With Acute Lymphoblast
 ic Leukemia\nEstimated primary completion: 11 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azd4512#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07109219
URL:https://assetmemo.bio/drug/azd4512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571746-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Surovatamig: Phase 2 readout est. (NCT07571746)
DESCRIPTION:Surovatamig\, phase 2.\nStudy: A Study to Assess the Effect of 
 Surovatamig in Adult Participants With Antibody-mediated Kidney Disease\nE
 stimated primary completion: 13 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07571746
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951959-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05951959)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treat
 ment Naïve Mantle Cell Lymphoma\nEstimated primary completion: 31 October
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595
 1959
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833154-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT03833154)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Plac
 ebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC)
  Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresec
 ted NSCLC Harboring an EGFR Mutation\nEstimated primary completion: 31 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 833154
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973564-2145@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06973564)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: JAB-23E73 in Adult Participants 
 With Advanced Solid Tumors With KRAS Alteration\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/j
 ab-23e73#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06973564
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819007-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06819007)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of Trastuzumab 
 Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line 
 Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)\nEstimat
 ed primary completion: 1 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06819007
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735637-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:AZD0120: Phase 3 readout est. (NCT07735637)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Phase III\, Mul
 ticentre Study to Evaluate Consolidation Treatment With AZD0120 Compared W
 ith ASCT\, in Participants With Newly Diagnosed Multiple Myeloma Who Are T
 ransplant Eligible (DURGA-6).\nEstimated primary completion: 2 November 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07735637
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097728-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281116
DTEND;VALUE=DATE:20281117
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06097728)
DESCRIPTION:Volrustomig\, phase 3.\nStudy: MEDI5752 in Combination With Car
 boplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma\nEstimated p
 rimary completion: 16 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06097728
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218809-11153@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281117
DTEND;VALUE=DATE:20281118
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07218809)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: AZD53
 35 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy
  in FRα-low Platinum-resistant Ovarian Cancer\nEstimated primary completi
 on: 17 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /torvutatug-samrotecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07218809
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Durvalumab\, phase 3\, Breast Cancer.\nStudy: A Phase III Rando
 mised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant T
 reatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast C
 ancer\nEstimated primary completion: 20 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024563-885@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281129
DTEND;VALUE=DATE:20281130
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07024563)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, IgA Nephropathy.\nStudy: St
 udy of Ravulizumab in Pediatric Participants With Primary IgAN\nEstimated 
 primary completion: 29 November 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07024563
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06535607-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06535607)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: Study of Volru
 stomig as Monotherapy or in Combination With Anti- Cancer Agents in Partic
 ipants With Advanced/Metastatic Solid Tumors\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 olrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06535607
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06746116-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06746116)
DESCRIPTION:Durvalumab\, phase 3\, Endometrial Cancer.\nStudy: A Study to E
 valuate the Use of Durvalumab in Combination With Platinum-based Chemother
 apy Followed by Durvalumab With Olaparib as First-line Treatment in Advanc
 ed or Recurrent Endometrial Cancer in Spain\nEstimated primary completion:
  30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/du
 rvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06746116
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06130553-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281204
DTEND;VALUE=DATE:20281205
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT06130553)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: A Study of AZD3470\
 , a PRMT5 Inhibitor\, Given as Monotherapy and in Combination in Patients 
 With MTAP Deficient Advanced/Metastatic Solid Tumors\nEstimated primary co
 mpletion: 4 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06130553
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Dato-DXd-based Combinations 
 in Participants With TROP2 NMR+ NSCLC\nEstimated primary completion: 16 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7941609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566195-1426@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:tozorakimab: Phase 3 readout est. (NCT07566195)
DESCRIPTION:tozorakimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Long-term Safety and Tolerability of Tozorakimab in Patients With 
 COPD and History of Exacerbations\nEstimated primary completion: 29 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tozorakimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0756
 6195
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109779-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06109779)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Rilvego
 stomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After R
 esection (ARTEMIDE-Biliary01)\nEstimated primary completion: 2 January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109779
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:AZD0120: Phase 3 readout est. (NCT07764978)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD0120 
 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated primary
  completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07764978
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Olaparib: Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Olaparib\, phase 1/2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684
 )-Based Treatment Combinations or Opevesostat Alone in Participants With M
 etastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)\nEsti
 mated primary completion: 15 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181161-11144@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:AZD0516: Phase 1/2 readout est. (NCT07181161)
DESCRIPTION:AZD0516\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD0516
  as Monotherapy and in Combination in Participants With Metastatic Prostat
 e Cancer\nEstimated primary completion: 18 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/azd0516#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07181161
URL:https://assetmemo.bio/drug/azd0516#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Rilvegostomig\, phase 3\, Endometrial Cancer.\nStudy: DESTINY-E
 ndometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostom
 ig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)
 \, Mismatch Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary
  completion: 19 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430306-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07430306)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in I
 mmunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus\n
 Estimated primary completion: 26 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07430306
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291037-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07291037)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Prev
 iously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Wi
 thout Actionable Genomic Alterations\nEstimated primary completion: 29 Jan
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07291037
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608354-11166@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Cliramitug: Phase 2 readout est. (NCT07608354)
DESCRIPTION:Cliramitug\, phase 2\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: A Study to Evaluate the Efficacy and Safety of Concomitant 
 Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for 
 Adults Participants With ATTR-CM\nEstimated primary completion: 6 February
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cliramitug#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760835
 4
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155226-2990@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:AZD3632: Phase 1/2 readout est. (NCT07155226)
DESCRIPTION:AZD3632\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study of 
 AZD3632 Monotherapy or in Combination With Anticancer Agents in Participan
 ts With Advanced Haematologic Malignancies With KMT2Ar\, NPM1m\, or Other 
 Genotypes Associated With HOX Overexpression\nEstimated primary completion
 : 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 zd3632#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07155226
URL:https://assetmemo.bio/drug/azd3632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 23 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647328-2423@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT07647328)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIb Study to Evaluate Camizestrant Plus Ribocicli
 b in ER-positive\, HER2-negative Advanced Breast Cancer\nEstimated primary
  completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/camizestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07647328
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878261-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06878261)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 7)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06878261
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883305-1507@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06883305)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 6)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06883305
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06005493-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290316
DTEND;VALUE=DATE:20290317
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06005493)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Gastric Cancer.\nStudy: Study of AZ
 D5863 in Adult Participants With Advanced or Metastatic Solid Tumors\nEsti
 mated primary completion: 16 March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06005493
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192614-11148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290329
DTEND;VALUE=DATE:20290330
SUMMARY:AZD6621: Phase 1/2 readout est. (NCT07192614)
DESCRIPTION:AZD6621\, phase 1/2\, Prostate Cancer.\nStudy: A Study to Learn
  How Safe AZD6621 is\, How Well it Works\, and How it Moves Throughout the
  Body Over Time\, in Adult Male Participants With Metastatic Prostate Canc
 er\nEstimated primary completion: 29 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd6621#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07192614
URL:https://assetmemo.bio/drug/azd6621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC
 )\nEstimated primary completion: 6 April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952024-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290422
DTEND;VALUE=DATE:20290423
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05952024)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail P
 atients With DLBCL\nEstimated primary completion: 22 April 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05952024
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ S
 tudy of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab
  Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer\n
 Estimated primary completion: 27 April 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897930-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06897930)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy to Investigate the Safety\, Tolerability\, and Efficacy of AZD0120 in
  Adults With Refractory SLE\nEstimated primary completion: 1 May 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06897930
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024706-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07024706)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Rel
 apsed After a Course of BTKi + BCL2i Combination\, With or Without Obinutu
 zumab\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07024706
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137144-11150@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:AZD3470: Phase 1/2 readout est. (NCT06137144)
DESCRIPTION:AZD3470\, phase 1/2.\nStudy: AZD3470 as Monotherapy or in Combi
 nation With Anticancer Agent(s) in Participants With Haematologic Malignan
 cies.\nEstimated primary completion: 3 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd3470#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06137144
URL:https://assetmemo.bio/drug/azd3470#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Withou
 t Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\
 nEstimated primary completion: 11 May 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525375-4297@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Glycopyrronium (PT001): Phase 2 readout est. (NCT07525375)
DESCRIPTION:Glycopyrronium (PT001)\, phase 2\, Asthma.\nStudy: A Phase II S
 tudy to Investigate Lung Function With 2 Different Doses of Inhaled Glycop
 yrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 
 12 Years of Age With Asthma\nEstimated primary completion: 23 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/glycopyrronium-pt001#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075253
 75
URL:https://assetmemo.bio/drug/glycopyrronium-pt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295821-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07295821)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Induction and Maintenance for Chemo-ineligible Stage I
 II Unresectable EGFR+ NSCLC: Single-arm Study\nEstimated primary completio
 n: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osime
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07295821
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129993-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Datopotamab Deruxtecan: Phase 2/3 readout est. (NCT07129993)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2/3\, Urothelial Carcinoma.\nStu
 dy: Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus G
 emcitabine Plus Carboplatin or Cisplatin in Participants With Locally Adva
 nced or Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab
 -deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07129993
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611110-11154@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Zadavotide guraxetan: Phase 3 readout est. (NCT07611110)
DESCRIPTION:Zadavotide guraxetan\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: AZD2265 Compared With Standard of Care in PSMA-
 positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)\nEsti
 mated primary completion: 4 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07611110
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546866-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05546866)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in
  NSCLC With Uncommon EGFRm\nEstimated primary completion: 30 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05546866
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992609-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06992609)
DESCRIPTION:Durvalumab\, phase 3\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06992609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934420-4382@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Pulmicort (Budesonide): Phase 3 readout est. (NCT07934420)
DESCRIPTION:Pulmicort (Budesonide)\, phase 3\, Asthma.\nStudy: An Efficacy 
 and Safety Study to Assess an Inhaled\, Fixed-dose\, Budesonide/Formoterol
  Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderat
 e Persistent Asthma\nEstimated primary completion: 30 July 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/budesonide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07934420
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221253-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07221253)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: A Study
  of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment
  of Biliary Tract Cancer (ARTEMIDE-Biliary02)\nEstimated primary completio
 n: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilv
 egostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07221253
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05071300-10798@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05071300)
DESCRIPTION:Wainua (Eplontersen)\, phase 3.\nStudy: A Study to Assess the L
 ong-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884\
 , IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyret
 in-Mediated Amyloid Polyneuropathy\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eplontersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05071300
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667493-10798@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05667493)
DESCRIPTION:Wainua (Eplontersen)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: An Extension Study to Assess Long-Term Safety of 
 Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (
 ATTR-CM)\nEstimated primary completion: August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eplontersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05667493
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081646-3183@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT07081646)
DESCRIPTION:AZD0120\, phase 1/2.\nStudy: A Phase 1b/2 Study of CAR T Cell T
 herapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory
  AL Amyloidosis.\nEstimated primary completion: 15 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07081646
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Rilvegostomig\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug V
 edotin in Combination With Capecitabine With or Without Rilvegostomig in P
 articipants With Advanced or Metastatic Gastric\, Gastroesophageal Junctio
 n\, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary
  completion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182682-2163@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zegfrovy (Sunvozertinib): Phase 3 readout est. (NCT07182682)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Ther
 apy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR
  Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery\nEsti
 mated primary completion: September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07182682
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761117-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290903
DTEND;VALUE=DATE:20290904
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07761117)
DESCRIPTION:elecoglipron\, phase 3\, Heart Failure.\nStudy: A Study to Inve
 stigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Parti
 cipants With HFpEF or HFmrEF\nEstimated primary completion: 3 September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07761117
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590934-11154@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290925
DTEND;VALUE=DATE:20290926
SUMMARY:Zadavotide guraxetan: Phase 1/2 readout est. (NCT07590934)
DESCRIPTION:Zadavotide guraxetan\, phase 1/2.\nStudy: Phase Ib/II Platform 
 Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prost
 ate Cancer\nEstimated primary completion: 25 September 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07590934
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-P
 anTumor04 (TP04)]\nEstimated primary completion: 30 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115043-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety of AZD6750 in Adult Participants With Selec
 t Advanced or Metastatic Solid Tumors\nEstimated primary completion: 2 Oct
 ober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegosto
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07115043
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000357-1050@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000357)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study of AZD0780 on Major Adverse CV Events in Patie
 nts With a History of ASCVD Events or at High Risk for a First Event\nEsti
 mated primary completion: 26 October 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07000357
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877818-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07877818)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Study of Neoadjuvant-adjuvant D
 urvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese
  Patients With Resectable GC/GEJC.\nEstimated primary completion: 1 Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07877
 818
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05526755-1958@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291122
DTEND;VALUE=DATE:20291123
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05526755)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected 
 Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carc
 inoma (NSCLC)\nEstimated primary completion: 22 November 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05526755
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0667706
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Phase III Study Investigating Heart Failure and Cardiovascular Death
  With Baxdrostat in Combination With Dapagliflozin\nEstimated primary comp
 letion: 17 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06677060
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06542250-5372@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:AZD5492: Phase 1/2 readout est. (NCT06542250)
DESCRIPTION:AZD5492\, phase 1/2.\nStudy: A Study to Evaluate Safety\, PK\, 
 PD and Efficacy of AZD5492\, a T Cell-engaging Antibody Targeting CD20 in 
 Subjects With R/R B-Cell Malignancies.\nEstimated primary completion: 18 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd5492
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 42250
URL:https://assetmemo.bio/drug/azd5492#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0674272
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Renal Outcomes and Cardiovascular Mortality Stu
 dy to Investigate the Efficacy and Safety of Baxdrostat in Combination Wit
 h Dapagliflozin in Participants With Chronic Kidney Disease and High Blood
  Pressure\nEstimated primary completion: 18 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Saruparib: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Saruparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Compa
 red With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in H
 R-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\, 
 BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 18
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarup
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06380751
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444567-1322@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT07444567)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: Roll-over St
 udy for Participants Who Have Completed a Previous Clinical Study With Ben
 ralizumab (Fasenra) and Benefit From Continued Treatment\nEstimated primar
 y completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/benralizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07444567
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, Study of First-line Dato-DXd in Combinati
 on With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expr
 ession (TC ≥ 50%) and Without Actionable Genomic Alterations\nEstimated 
 primary completion: 28 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640295-2145@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT07640295)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: Study of JAB-23E73 in Combinatio
 n With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Ge
 ne Alterations\nEstimated primary completion: 31 December 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07640295
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olaparib: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Olaparib\, phase 2\, Breast Cancer.\nStudy: Study of Patritumab
  Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participant
 s With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Posit
 ive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEstim
 ated primary completion: 31 December 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868277-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300117
DTEND;VALUE=DATE:20300118
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06868277)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for 
 First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer\n
 Estimated primary completion: 17 January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06868277
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03813407-608@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300221
DTEND;VALUE=DATE:20300222
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 03813407)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3.\nStudy: An 
 Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patien
 ts With Hyperkalaemia\nEstimated primary completion: 21 February 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sodium-zirconium-cyclosi
 licate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03813407
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022483-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07022483)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study of Trastuzuma
 b Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC
  3+/2+) Endometrial Cancer in Adjuvant Setting\nEstimated primary completi
 on: 26 February 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07022483
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the
  First-line Treatment of Subjects With Advanced or Metastatic NSCLC Withou
 t Actionable Genomic Alterations\nEstimated primary completion: 4 March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05215340
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952557-2423@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05952557)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: An Ad
 juvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2
 - Early Breast Cancer (CAMBRIA-2)\nEstimated primary completion: 4 March 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camizestrant#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595255
 7
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Rilvegostomig\, phase 3\, Hepatocellular Carcinoma.\nStudy: Pha
 se III Study of Rilvegostomig in Combination With Bevacizumab With or With
 out Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEsti
 mated primary completion: 15 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446855-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300329
DTEND;VALUE=DATE:20300330
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT07446855)
DESCRIPTION:Saruparib\, phase 1/2.\nStudy: Study of AZD4956 as Monotherapy 
 and in Combination With Anti-Cancer Agents in Participants With Advanced/M
 etastatic Homologous Recombination Deficient Solid Tumours\nEstimated prim
 ary completion: 29 March 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/saruparib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07446855
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06129864-1985@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06129864)
DESCRIPTION:Volrustomig\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Global Study of Volrustomig (MEDI5752) for Participants With Unr
 esected Locally Advanced Head and Neck Squamous Cell Carcinoma Following D
 efinitive Concurrent Chemoradiotherapy\nEstimated primary completion: 17 A
 pril 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomi
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 129864
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-bas
 ed Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Canc
 er\nEstimated primary completion: 24 April 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-3339@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: A Stu
 dy of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents 
 for Mature B-Cell Malignancies\nEstimated primary completion: 20 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1959@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nE
 stimated primary completion: 28 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215585-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07215585)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: AZD0486 
 1L Therapy for Elderly or Unfit Participants With LBCL\nEstimated primary 
 completion: 10 June 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/surovatamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07215585
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851025-11153@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Torvutatug samrotecan: Phase 3 readout est. (NCT07851025)
DESCRIPTION:Torvutatug samrotecan\, phase 3\, Ovarian Cancer.\nStudy: Torvu
 tatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homolog
 ous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovaria
 n Cancer\nEstimated primary completion: 28 June 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07851025
URL:https://assetmemo.bio/drug/torvutatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-306@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0762430
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Evaluate the Effect of Balcinrenone/Da
 pagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07624305
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692738-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06692738)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-
 small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1 July 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06692738
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2164@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dua
 l HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retr
 eatment With T-DXd\nEstimated primary completion: 4 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789483-11166@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:Cliramitug: Phase 3 readout est. (NCT07789483)
DESCRIPTION:Cliramitug\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: An Open-Label Study to Evaluate the Long-Term Safety and Ef
 ficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy\nEs
 timated primary completion: 11 July 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cliramitug#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07789483
URL:https://assetmemo.bio/drug/cliramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722988-873@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT07722988)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Myelodysplastic Syndromes.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592
 ) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
 \nEstimated primary completion: September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/roxadustat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07722988
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630714-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Anifrolumab: Phase 2 readout est. (NCT07630714)
DESCRIPTION:Anifrolumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Investigate Pharmacokinetics\, Pharmacodynamics\, and Safety of 
 Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age 
 With Systemic Lupus Erythematosus\nEstimated primary completion: 2 Septemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/anifrolumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763
 0714
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911553-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07911553)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: A Study 
 to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80
  Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Sco
 re 2 to 5\nEstimated primary completion: 2 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07911553
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1980@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Urothelial Carcinoma.\nStudy
 : An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd +
  Rilvegostomig vs SoC in Adult Participants With High-risk MIUC\nEstimated
  primary completion: 11 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753993-148@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20301004
DTEND;VALUE=DATE:20301005
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07753993)
DESCRIPTION:elecoglipron\, phase 3\, Chronic Kidney Disease.\nStudy: A Stud
 y to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult
  Participants With Chronic Kidney Disease.\nEstimated primary completion: 
 4 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eleco
 glipron#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07753993
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627647-1986@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20301118
DTEND;VALUE=DATE:20301119
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06627647)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous 
 NSCLC\nEstimated primary completion: 18 November 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06627647
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681596-3202@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:AZD4045: Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:AZD4045\, phase 1/2\, Multiple Myeloma.\nStudy: A Modular\, Pha
 se I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With Rel
 apsed or Refractory Multiple Myeloma\nEstimated primary completion: 6 Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd4045#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07681596
URL:https://assetmemo.bio/drug/azd4045#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05367440-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05367440)
DESCRIPTION:Saruparib\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD53
 05 When Given in Combination With New Hormonal Agents in Patients With Met
 astatic Prostate Cancer\nEstimated primary completion: 11 April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05367440
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711002-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Saruparib: Phase 3 readout est. (NCT07711002)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib in Com
 bination With Physician's Choice of ARPI in Patients With mHSPC Previously
  Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression 
 and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)\nEstimated primary completion: 30 May 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07711002
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509151-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20310829
DTEND;VALUE=DATE:20310830
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07509151)
DESCRIPTION:Surovatamig\, phase 3.\nStudy: Surovatamig as Consolidation The
 rapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocyt
 ic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)\nEst
 imated primary completion: 29 August 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07509151
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549595-5561@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20311126
DTEND;VALUE=DATE:20311127
SUMMARY:Surovatamig: Phase 3 readout est. (NCT06549595)
DESCRIPTION:Surovatamig\, phase 3\, Follicular Lymphoma.\nStudy: A Study of
  Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular L
 ymphoma Patients\nEstimated primary completion: 26 November 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06549595
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218887-11162@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320127
DTEND;VALUE=DATE:20320128
SUMMARY:ALXN2350: Phase 1/2 readout est. (NCT07218887)
DESCRIPTION:ALXN2350\, phase 1/2\, Dilated Cardiomyopathy.\nStudy: ALXN2350
  in Adult Participants With BAG3-Associated Dilated Cardiomyopathy\nEstima
 ted primary completion: 27 January 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/alxn2350#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07218887
URL:https://assetmemo.bio/drug/alxn2350#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691970-5367@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20321230
DTEND;VALUE=DATE:20321231
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07691970)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: R
 ollover Study for Participants Who Have Completed a Previous Clinical Stud
 y With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Trea
 tment\nEstimated primary completion: 30 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07691970
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Olaparib: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Olaparib\, phase 3\, Breast Cancer.\nStudy: A Clinical Study of
  Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cancer 
 (MK-2870-032)\nEstimated primary completion: 23 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952803-2090@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Saruparib: Phase 3 readout est. (NCT06952803)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: A Study of Metas
 tases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT i
 n Men With High-risk Prostate Cancer With a BRCA Mutation\nEstimated prima
 ry completion: 31 March 2033. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06952803
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-2028@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Olaparib: Phase 3 readout est. (NCT03486873)
DESCRIPTION:Olaparib\, phase 3.\nStudy: Long-term Safety and Efficacy Exten
 sion Study for Participants With Advanced Tumors Who Are Currently on Trea
 tment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYN
 OTE-587)\nEstimated primary completion: 4 August 2043. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
